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PAR2 signaling is required for oxidative burst and phagocytosis in neu-
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TF-dependent activity of neutrophils in aPL-IgG–treated mice is not 





















TF/FVIIa signaling is required for oxidative burst and phagocytosis in 
neutrophils from aPL-IgG–treated mice. To confirm the role of TF/






























































Treatment	 Mean	Ct	 ΔCt	 ΔΔCt	 2–ΔΔCt
	 Target	 GAPDH
TF
Untreated 33.3 22.1 11.2 ± 1.2 0 ± 0.78
aPL-IgG 27.8 21.5 6.3 ± 2.2 –4.9 ± 0.9 29.9 ± 0.7A
PAR2
Untreated 28.7 22.1 6.6 ± 1.8 0 ± 1.0
aPL-IgG 25.7 21.5 4.2 ± 1.1 –2.4 ± 1.2 5.3 ± 0.4B
Relative quantification of TF and PAR2 between polymorphonuclear 
neutrophils from aPL-IgG–treated and untreated mice. The comparison 
was performed in pairs using the same target gene and the same neu-
trophil samples (n = 5 mice per group). ΔCt, mean target Ct minus mean 
GAPDH Ct; ΔΔCt, mean ΔCt aPL-IgG–treated minus mean ΔCt untreat-
ed for the same target gene; 2–ΔΔCt, normalized target gene amount 
relative to target gene amount in untreated mice. ΔΔCt equals 0 when 
the neutrophils of interest are used as calibrator. AExpression increased 
29.9-fold compared with untreated neutrophils (P < 0.01). BExpression 
increased 5.3-fold compared with untreated neutrophils (P < 0.01).
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Statins prevent fetal injury in aPL-IgG–treated mice. Statins are com-
pounds commonly used to reduce the level of cholesterol in the 




































Simvastatin downregulates TF and PAR2 expression and diminishes ROS 
production and phagocytosis in neutrophils. Knowing that the protective 
Figure 1
PAR2 is required for aPL-IgG–induced neutrophil activity. (A) Immunohistochemical detection of TF and PAR2 on neutrophils from aPL-IgG– and 
NH-IgG–treated mice. Original magnification, ×400. (B) ROS production, measured as DHR-positive cells, on whole blood neutrophils from 
aPL-IgG–treated mice. The number of DHR-positive neutrophils increased in aPL-IgG–treated wild-type mice compared with untreated mice. 
ROS production in neutrophils did not increase in aPL-IgG–treated Par2–/– mice. (C and D) Phagocytic cells and DHR-positive cells in wild-type 
and Par2–/– mice. The percentage of phagocytic (C) and DHR-positive (D) neutrophils increased in aPL-IgG–treated wild-type mice compared 
with NH-IgG–treated mice. The absence of PAR2 prevented aPL-IgG–induced ROS production and phagocytosis. Incubation of neutrophils 
from Par2–/– mice with PMA induced increased ROS generation and phagocytosis, which indicates that the capacity of Par2–/– mice to generate 
oxidants or in phagocytosis is normal. (E and F) ROS production and phagocytosis in neutrophils from aPL-IgG–treated mice. (E) Neutrophils 
from Par1–/– mice treated with aPL-IgG showed increased ROS generation (E) as well as phagocytosis similar to aPL-IgG–treated wild-type mice 
(F). Increased ROS production was also observed in neutrophils from mice treated with hirudin or FPX in addition to aPL-IgG. n = 5–7 per group. 
*P < 0.05 versus NH-IgG; #P < 0.05 versus wild type. Data in C–F are mean ± SD.
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TF/FVIIa/PAR2 signaling is required for aPL-IgG–induced increase in neutrophil activity. (A) Effect of 10H10 and 5G9 on neutrophil phagocytosis 
and neutrophil ROS generation in aPL-IgG–treated mice, as determined by FACS. aPL-IgG–induced phagocytosis and ROS generation were pre-
vented by 10H10, but not 5G9. Mouse IgG1 (mIgG) was used as isotype control. (B) TF expression, ROS production, and phagocytosis in neutro-
phils from NH-IgG–treated wild-type mice, aPL-IgG–treated wild-type mice, and aPL-IgG–treated TFΔCT/ΔCT mice. aPL-IgG–induced ROS production 
and phagocytosis was not observed in TFΔCT/ΔCT mice. *P < 0.05, **P < 0.01 versus NH-IgG. n = 5 mice per group. All data are mean ± SD.
Figure 3
Par2–/– mice are protected from trophoblast oxidative injury 
and fetal death. Pregnant Par2–/– or wild-type mice were given 
10 mg aPL-IgG or NH-IgG i.p. on days 8 and 12. (A) Mice 
were killed on day 15 of pregnancy, uteri were dissected, and 
FRF was calculated as described in Methods. In matings of 
wild-type mice, approximately 40% of the embryos of mice 
treated with aPL-IgG were resorbed; in contrast, Par2–/– mice 
showed a reduction in aPL-IgG–induced FRF. *P < 0.05 ver-
sus NH-IgG. n = 5–7 mice per group. Data are mean ± SD. (B 
and C) Mice were killed on day 8, 2 h after aPL-IgG or NH-IgG 
injection. Uteri were dissected, and decidua sections were cut 
and stained with an anti-C3 antibody (B) or DHE (C) to mea-
sure superoxide generation. (B) The chromogen was DAB 
(brown), and the counterstain was hematoxylin. In aPL-IgG– 
treated wild-type mice, there was extensive C3 staining 
(brown) in deciduae as well as embryo debris (ED). In con-
trast, the decidual tissue from aPL-IgG–treated Par2–/– mice 
showed minimal staining for C3 at the ectoplacental cone (ec) 
and intact embryo (E). (C) aPL-IgG–induced superoxide pro-
duction in wild-type mice was attenuated in Par2–/– mice. Oxi-
dative damage in deciduae from aPL-IgG–treated PAR2 mice 
was minimal and not different from that in NH-IgG–treated 
wild-type mice. Scale bars: 100 μm (B); 40 μm (C).
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matory  diseases  (29).  We  previously  reported 


































Simvastatin prevents pregnancy loss in aPL-IgG–treated mice. (A and B) Pregnant 
C57BL/6 mice were given 10 mg aPL-IgG or NH-IgG i.p. on days 8 and 12, and some 
also received 20 μg simvastatin i.p. 18 h before administration of aPL-IgG (n = 5–11 
mice per group). (A) Mice were killed on day 15 of pregnancy, uteri were dissected, and 
FRF was calculated. Treatment with simvastatin prevented fetal loss. †P < 0.01 versus 
aPL-IgG plus simvastatin. Data are mean ± SD. (B) Uteri from day 15 of pregnancy. 
There were 5 fetuses and 3 resorptions (asterisks) in the uterus of an aPL-IgG–treated 
mouse, while the uterus of a mouse that received aPL-IgG plus simvastatin contained 
7 fetuses and no resorptions, similar to mice treated with NH-IgG (not shown). Data are 
representative of observations in 5–8 mice per group. (C) Mice were killed on day 8, 2 h 
after aPL-IgG or NH-IgG injection. Decidua sections were stained with an anti-C3 anti-
body as in Figure 3. In aPL-IgG–treated wild-type mice, there was extensive C3 staining 
(brown) in deciduae as well as embryo debris. In contrast, the decidual tissue from mice 
treated with aPL-IgG plus simvastatin showed minimal staining for C3 and intact embryo. 
(D) FACS analysis of DAF expression on trophoblast-like BeWo cells. There was no 
difference in DAF expression between untreated BeWo cells and BeWo cells incubated 
with 10 μg/ml simvastatin. Scale bars: 1 cm (B); 200 μm (C, left); 50 mm (C, right).
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Statins inhibit TF and PAR2 synthesis and prevent neutrophil oxidative burst and oxidative damage in aPL-IgG–treated mouse placentas. 
Pregnant C57BL/6 mice were given aPL-IgG or NH-IgG as in Figure 3; some also received 20 μg simvastatin or 5 μg pravastatin i.p. 18 h before 
aPL-IgG administration (n = 5–10 mice per group). (A) On day 8, 2 h after aPL-IgG or NH-IgG injection, a blood sample was drawn in order to 
determine ROS production and phagocytosis in neutrophils by FACS, measured as the number of DHR-positive cells. aPL-IgG increased ROS 
production, whereas simvastatin prevented neutrophil oxidative burst in aPL-IgG–treated mice. The number of DHR-positive neutrophils was 
similar between NH-IgG treated and aPL-IgG plus simvastatin–treated mice. (B and C) RT-PCR analysis was performed in isolated neutrophils 
to quantify TF and PAR2 gene expression. Neutrophils from aPL-IgG–treated mice showed a 28-fold increase in TF mRNA (B) and a 5-fold 
increase in Par2 mRNA (C). Simvastatin prevented aPL-IgG–induced increase in TF and PAR2 synthesis. (D) Mice were killed on day 8, and 
deciduae were removed to determine superoxide generation using DHE fluorescence. Increased free radical–mediated lipid peroxidation was 
observed in deciduae from aPL-IgG–treated mice. No oxidative damage was observed in NH-IgG and aPL-IgG plus simvastatin–treated mice. 
Scale bars: 50 μm. (E) Mice were killed on day 15 of pregnancy, uteri were dissected, and FRF was calculated. Similar to the effects of simvas-
tatin, pravastatin treatment prevented fetal loss. ‡P < 0.05 versus aPL-IgG plus simvastatin or pravastatin as appropriate.
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Respiratory burst activity in neutrophils. Intracellular ROS production was 
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